Objectives To evaluate the cost-effectiveness of a booster strategy in the United States.
Methods We developed a decision-analytic Markov model of COVID-19 to evaluate the cost …

Objective To evaluate COVID-19 vaccine breakthrough infections among
immunocompromised (IC) individuals. Methods Individuals vaccinated with BNT162b2 were …

Importance The BNT162b2 vaccine showed high efficacy against COVID-19 in a phase III
randomized clinical trial. A vaccine effectiveness evaluation in a real-world setting is …

Background Globally, recommendations are expanding for third (booster) doses of
BNT162b2 (Pfizer–BioNTech). In the United States, as of November 19, 2021, boosters were …

Importance Administration of a BNT162b2 booster dose (Pfizer-BioNTech) to fully
vaccinated individuals aged 60 years and older was significantly associated with lower risk …

Importance Few studies have evaluated the waning of vaccine effectiveness against severe
outcomes caused by SARS-CoV-2 Omicron infection. Hong Kong is providing inactivated …

Background The rapid vaccination campaign against COVID-19 in Israel relied on the
BNT162b2 vaccine. We performed a longitudinal analysis of multiple cohorts, using …

Background Active immunization with the BNT162b2 vaccine (Pfizer–BioNTech) has been a
critical mitigation tool against severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Correspondence 1664 www. thelancet. com/infection Vol 22 December 2022 emergency
department encounters only in the first 3 months after a third dose of vaccine (table). At 6 …

Background: Following emergency use authorization of the Pfizer/BioNTech mRNA SARS-
CoV-2 vaccine, BNT162b2, the Ministry of Health (MoH) launched a campaign to immunize …